ClinicalTrials.gg
RecruitingNCT06683014MDMA in BPDUpdated Oct 22, 2026

MDMA in Borderline Personality Disorder

A Phase 2 interventional study of MDMA in Borderline Personality Disorder, sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Yale University · Phase 2, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 22, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Borderline Personality Disorder with a site in United States — 15 open to participants now, 17 under way, none of them phase 3. Borderline Personality Disorder · United States.

Planned enrollment
64th of 71
10 · median 56
Started
2025
with 3 others
Phase 2
16 of 81
1 open now
Primary completion
2027-06
later than 8 of 16 live
Registered
74th of 81
by date
Lead sponsor
5 of 81
Yale University

Among the 81 studies in Borderline Personality Disorder with a site in United States, this one is the 64th largest by planned enrollment of the 71 interventional ones that give a count, is one of 4 that started in 2025, is one of 16 in phase 2, reaches primary completion later than 8 of the 16 other live ones, and was the 74th registered.

Borderline Personality Disorder

279 studies on the registry are indexed under Borderline Personality Disorder; 70 are open to participants now.

Browse Borderline Personality Disorder studies →

Open to participants now

15 of the 81 studies in Borderline Personality Disorder with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Borderline Personality Disorder studies recruiting now, 18 (37%) set no upper age limit and 30 (61%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Borderline Personality Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to test the effects of MDMA (3,4-methylenedioxymethamphetamine) on social cognition in adults with Borderline Personality Disorder.

03

Conditions studied

  • Borderline Personality Disorder

Keywords

  • 3,4-methylenedioxymethamphetamine
  • social cognition
04

Who can participate

The criteria were revised on the registry on Oct 22, 2026. See what changed

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults between the ages of 18-60 years
  • Body weight between 110 and 210 pounds. Minimum (BMI) 16.5.
  • Able to swallow pills.
  • Must provide a contact (relative, spouse, close friend or other support person) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable and must sign release of information for this contact person.
  • Must reside within 200 miles (or within a 4-hour commute) to the Connecticut Mental Health Center (CMHC) in New Haven.
  • People of must agree to utilize a highly effective method of (including the following, in accordance with Clinical Trials Facilitation and Coordination Group (CTFG) guidelines: combined estrogen and progestogen containing hormonal contraception associated with inhibition of ovulation, including oral, intravaginal, and transdermal administrations; estrogen-only hormonal contraception associated with inhibition of ovulation, including oral, injectable, and implantable forms; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomized partner; abstinence from sexual activity with biological males) and for one month prior to dosing and for the duration of the two week follow-up period.
  • Able to provide written according to Yale IRB guidelines.
  • Able to read and write English proficiently.
  • Diagnosis of BPD, as determined by the Diagnostic Interview for Personality Disorders BPD questions (DIPD), including endorsement of the criteria for abandonment fears and for stormy relationships.
  • No exposure to MDMA in the last 6 months, and no more than 10 lifetime uses of ecstasy.
  • Agree not to drive a motor vehicle for 24 hours after the treatment day. Agree to identify a support person to accompany them home after the medication day.
  • Are willing to remain overnight at the study site after each experimental session until the next morning if recommended by the study physician
  • Currently not taking medications (antidepressants, antipsychotics, mood stabilizers, stimulants).
  • Medications not on the contraindicated list must be reviewed and approved by the study PI
  • For people in mental health care, signs releases for the study investigators to communicate with their mental healthcare provider and medical doctor(s) about their medical and mental health history and their mental and medical status during the study. When contacted, the mental healthcare provider confirms the ongoing treatment relationship.
  • For people not in mental health care acknowledges receipt of local resources for mental healthcare.
  • For all participants, acknowledges receipt of local emergency resources

Exclusion criteria

Exclusion Criteria:

  • History of bipolar disorder, schizophrenia or schizoaffective disorder or currently exhibiting psychotic features as determined by the Structured Clinical Interview for DSM5 (SCID-5) and/or clinician assessment.
  • Lifetime diagnosis of autism.
  • Serious suicide risk in the past 6 months, as assessed by Columbia Suicide Severity Rating Scale (CSSRS) type 4 or 5 ideation, or suicidal behavior (CSSRS item) or preparatory acts (CSSRS item).
  • Any current substance use disorder (in the last 1 month) per SCID interview for alcohol or non-alcohol substances; or a positive pre-study (screening) urine drug screen.
  • Any severe substance use disorder during the last 6 months.
  • Any significant history of serious medical or neurological illness (including history of stroke, myocardial infarction, heart failure, cardiac arrhythmia, diabetes, family history of long- syndrome, etc.)
  • Any signs of major medical or neurological illness on examination, screening, or laboratory tests. For QTc, we would exclude for QTcf >450. For liver function tests (, ALT), we will exclude for values more than 2.5 times the for our laboratory. For kidney function, we would exclude for \< 90 (n.b. our laboratory does use the contemporary non-race based formula for eGFR). electrolyte imbalances (sodium, potassium values out of range) will also be exclusionary (clinical significance to be determined by study MD review). A participant with a clinical abnormality may be included only if the study physician considers the abnormality will not introduce additional risk factors and will not interfere with the study procedure.
  • History of valvulopathy or pulmonary hypertension (due to evidence of 5HT2B receptor agonism by MDMA)
  • History of uncontrolled hypertension with baseline blood pressure above 130 mmHg (systolic) and over 90 mmHg (diastolic). Any history of syncope and/or study baseline blood pressure below 90 mmHg (systolic).
  • History of tachycardia with baseline heart rate above 90 beats per minute.
  • Current pregnancy or breastfeeding as assessed by patient report or by urine pregnancy test.
  • Taking any medications: antidepressants, mood stabilizers, antipsychotics, stimulants. No patient will be encouraged to discontinue medications for the study. We will allow people to participate who stopped contraindicated medications at least five half-lives before baseline assessments.
  • to non-MDMA ingredients of the medicine product (IMP), namely mannitol, magnesium stearate, and hydroxypropylmethylcellulose.
  • Herbal and dietary supplements will be reviewed on a case-by-case basis by the sponsor-PI for decision about safety.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Open-Label MDMA

    Participants will receive one dose of open-label 3,4-methylenedioxymethamphetamine (MDMA).

    Drug: MDMA

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Self-Reported Social Cognition After 1 Dose of MDMA.

    Defined as sociability visual-analogue scale (VAS) score. Total score range is 0-100, higher scores indicating more sociability.

    Time frame: From baseline (immediately before drug dose) to 2 hours after drug dose on the same day.

Secondary outcomes

  1. Change from baseline in emotion appraisal on facial emotion recognition task score, on same day after drug administration.

    The facial-emotion recognition task is a computer-based cognitive task for measuring ability to recognize facial emotions, that yields accuracy scores for positive and negative emotions. Possible scores range from 0 (poor facial emotion recognition) to 100% (excellent facial emotion recognition).

    Time frame: From baseline (immediately before drug dose) to 2 hours after drug dose on the same day.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Currently there is no plan to share to share individual participant data.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2025 (actual). Primary completion is estimated for Jun 2027, 21 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Sep 2026 → Jun 2027 and completion Sep 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2024
First posted
Nov 12, 2024
StartActual
Sep 5, 2025
Primary completionEst.
Jun 2027was Sep 2026
CompletionEst.
Jun 2027was Sep 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Jun 2027
Oct 22, 2026
Study completion
Sep 2026→Jun 2027
Oct 22, 2026
Eligibility
1 inclusion criterion added
What changed in the criteria
Inclusion criteria
  • AddedMust reside within 200 miles (or within a 4-hour commute) to the Connecticut Mental Health Center (CMHC) in New Haven.
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Primary completion Sep 2026→Jun 2027
    Study completion Sep 2026→Jun 2027
    Eligibility 1 inclusion criterion added
    What changed in the criteria
    Inclusion criteria
    • AddedMust reside within 200 miles (or within a 4-hour commute) to the Connecticut Mental Health Center (CMHC) in New Haven.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06683014
Lead sponsor
Yale University
Collaborators
Connecticut Mental Health Center
Responsible party
Sarah Fineberg (Assistant Professor of Psychiatry, Yale University) — Principal investigator
First posted
Nov 12, 2024
Start date
Sep 5, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Sarah K Fineberg, MD, PhD
Contact
fineberg.lab@yale.edu
(203) 974-7265
Alexandra A Alario, PhD
Contact
fineberg.lab@yale.edu
(203) 974-7265
Sarah K Fineberg, MD, PhD
principal investigator · Yale University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion